产品展示更多>>
- IPI-145 1201438-56-3
- IPI-145 1201438-56-3
IPI-145 1201438-56-3
产品描述 描述 Duvelisib is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.
纯度 >98%储存/保存方法 Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.基本信息 别名 IPI-145; INK1197外观 白色至类白色粉末可溶性/溶解性 DMSO : 77 mg/mL (184.7 mM)生物活性 靶点 PI3Kα,PI3Kβ,PI3Kγ, PI3KδIn vitro(体外研究) IPI-145 suppresses murine/human B-cell proliferation with EC50 of 0.5 nM/0.5 nM and also inhibits human T-cell proliferation with EC50 of 9.5 nM.In vivo(体内研究) IPI-145 (10 mg/kg, p.o.) shows well pharmacokinetics with Cmax and AUC of 390 ng/mL and 137 ng•h/mL in mouse and rat. IPI-145 (10 mg/kg) is active in murine DTH model with ~50% ear swelling. IPI-145 (10 mg/kg) demonstrates dose-dependent effect in rat collagen induced arthritis (CIA) model. IPI-145 prevents inflammation and protects joint bone and cartilage in the rat CIA model. IPI-145 (10 mg/kg,QD) demonstrates activity in rat adjuvant induced polyarthritis model.研究领域 研究领域 CancerCancer MetabolismCancerTumor biomarkersDrug DiscoverySmall Molecule DrugLead Compound DiscoveryIPI-145 1201438-56-3温馨提示：本产品仅作科研实验使用，不支持临床等研究